EpiPen Pricing Fury, Pfizer’s $14B Megabid for Medivation & Denali Grabs $130M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Karuna’s Schizophrenia Advance, FDA Clears HER2-Low Drug, & Pfizer Buys GBT
Alnylam’s Big Day, Amgen Buys ChemoCentryx & a Borisy Startup
Novavax Cleared, Verve’s Gene Editing Milestone, & Third Rock Reaches Out
Merck Circles Seagen, Arch Triples Down & Novartis Cuts 8,000 Jobs